PROGNOSTIC UTILITY OF SQUAMOUS CELL CARCINOMA ANTIGEN IN CARCINOMA OF THE CERVIX: ASSOCIATION WITH PRE- AND POSTTREATMENT FDG-PET
PROGNOSTIC UTILITY OF SQUAMOUS CELL CARCINOMA ANTIGEN IN CARCINOMA OF THE CERVIX: ASSOCIATION WITH PRE- AND POSTTREATMENT FDG-PET
复制标题
DOI：
10.1016/j.ijrobp.2010.06.008
复制
发表时间：
2011-11-01
影响因子：
7
通讯作者：
Schwarz, Julie K.
中科院分区：
文献类型：
--
作者：
Olsen, Jeffrey R.;Dehdashti, Farrokh;Schwarz, Julie K.
目的：鳞状细胞癌抗原（SCC Ag）是宫颈鳞状细胞癌（SCC）的血清生物标志物。我们研究了放化疗前和完成时SCC Ag水平的预后意义，并将这些水平与治疗前和治疗后正电子发射断层扫描/计算机断层扫描（PET/CT）使用[（18）F]氟脱氧葡萄糖（FDG）的结果进行了比较。方法和材料：63名妇女接受了明确的放化疗宫颈SCC的记录进行了审查。在放疗前和放疗结束时获得SCC Ag水平。患者根据其治疗前SCC Ag水平分为两组（诊断时>30 ng/mL vs. 30 ng/mL），与SCC Ag 530 ng/mL的患者相比，治疗前FDG-PET/CT显示淋巴结疾病更晚期（p = .002）。在放化疗完成时SCC Ag正常化的女性在治疗后3个月的FDG-PET/CT中比SCC Ag未正常化的女性更有可能获得完全代谢反应（p = .006）。诊断时SCC Ag水平30 ng/mL的患者2年PFS为73%（p < .0001）。2年PFS为62%的患者的SCC Ag正常化的放化疗完成相比，0%的SCC Ag没有正常化（p = .0004）。结论：升高SCC Ag诊断和失败的SCC Ag正常化在完成治疗与不完全的代谢反应和PFS下降。(C)2011 Elsevier Inc.
Purpose: Squamous cell carcinoma antigen (SCC Ag) is a serum biomarker for squamous cell carcinoma (SCC) of the cervix. We investigated the prognostic significance of SCC Ag levels before and at the completion of chemoradiotherapy and compared these levels with the results of pre- and posttreatment positron emission tomography/computed tomography (PET/CT) using [(18)F]fluorodeoxyglucose (FDG).Methods and Materials: The records of 63 women who underwent definitive chemoradiotherapy for SCC of the cervix were reviewed. SCC Ag levels were obtained before and at the completion of radiotherapy. Patients were divided into two groups on the basis of their pretreatment SCC Ag level (>30 ng/mL vs. 30 ng/mL at diagnosis had more advanced lymph node disease on pretreatment FDG-PET/CT than those with SCC Ag 530 ng/mL (p = .002). Women whose SCC Ag normalized at the completion of chemoradiotherapy were more likely to have a complete metabolic response on their 3-month posttreatment FDG-PET/CT than those whose SCC Ag did not normalize (p = .006). The 2-year PFS was 73% for patients with a SCC Ag level 30 ng/mL at diagnosis (p < .0001). The 2-year PFS was 62% for patients whose SCC Ag normalized at the completion of chemoradiotherapy compared with 0% for those whose SCC Ag did not normalize (p = .0004).Conclusion: Elevated SCC Ag at diagnosis and failure of the SCC Ag to normalize at the completion of treatment are associated with incomplete metabolic response and decreased PFS. (C) 2011 Elsevier Inc.